---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS301 part C"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: VTS301 part C. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 2 further headings. 40 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/vts301-part-c"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS301 part C

<a id="heading-3.1.3"></a>

## 3.1.3 VTS301 Part C

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Primary objective of Part C, before and after January 2021

> “The primary study objective in Part C is to evaluate the long-term safety, tolerability, and efficacy of VTS-270. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective for Part C has been changed to evaluate only longer-term safety and tolerability.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.1-2"></a>

#### Registry statement of purpose

> “This study is to evaluate how safe and effective adrabetadex is for participants with Niemann-Pick Type C1 (NPC1) disease who experience neurologic symptoms (listed under Keywords).”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.1-3"></a>

#### Secondary objective: intrathecal access device substudy

> “Assess the safety and tolerability of the B. Braun Celsite Spinal Access Port utilized to administer VTS-270 (device safety and tolerability substudy).”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.1-4"></a>

#### VTS-270-302 primary objective

> “To evaluate the long-term safety and tolerability of adrabetadex in subjects transitioning from Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry study dates and enrollment

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-12-23” |
| Primary completion (actual) | “2022-04-11” |
| Study completion (actual) | “2022-04-11” |
| Enrollment (actual) | “66” |
| Results first posted | “2023-08-29” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-2"></a>

#### Number of locations and facilities in Washington, DC and Switzerland

> “This study has 30 locations”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

| Country | Facility |
| --- | --- |
| United States | “Children's National Medical Center” |
| Switzerland | “INSELSPITAL, Universitätsspital Bern” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-3"></a>

#### Separate registration of Part C

> “Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.2-4"></a>

#### End of dosing in 2021

> “Treatment with VTS-270 should be discontinued as soon as possible; in consideration of the need to determine a transition plan, treatment with VTS-270 will be permitted for up to an additional 9 months (20 October 2021).”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

> “The last doses for the VTS-301 study were administered and the study closeout process is well underway.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.3.2-5"></a>

#### VTS-270-302: registry dates and site in Costa Rica

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2019-12-02” |
| Study completion (actual) | “2021-10-18” |
| Enrollment (actual) | “2” |
| Location | “Hospital Clinica Biblica” |

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

> “Any country may serve as a location for an activated study site, including but not limited to Costa Rica, Mexico, and China.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Open-label, single-group extension

> “Part C (NCT04958642) was an open-label extension that enrolled 66 patients including 35 LEMBAZ-treated patients from Parts A and B, 18 treatment-naïve, and 13 LEMBAZ-treated patients from Trial 2.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “In Part C, all participants will receive study drug.”
> “Participants in Part C will receive adrabetadex until the investigator considers adrabetadex to no longer be beneficial to the participant, or the development program is discontinued.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.3-2"></a>

#### Efficacy endpoints planned for Part C

> “The change from baseline to each assessment in a composite outcome that is the sum of the ambulation, cognition, fine motor, and swallowing components of the NPC-SS”
> “Change from baseline in the EQ-5D-3L questionnaire at each assessment”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.3-3"></a>

#### Device substudies and termination of enrollment

> “A European site-specific substudy of the safety and tolerability of the device was conducted in subjects who met the eligibility criteria to have a device implanted for VTS-270 infusion.”
> “A European site-specific substudy of plasma and CSF PK of VTS-270 administered via the device was planned but not conducted under Part C, as no subjects consented.”
> “The VTS270 development program has been terminated by the sponsor. No new subjects are permitted to enroll in the study.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

#### VTS-270-302: open-label continuation study for VTS301 participants

> “This is a multicenter, multinational, open-label study of VTS-270 to evaluate the long-term safety and tolerability of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 (Parts A/B [NCT02534844] and Part C [NCT04958642]) with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

> “This study is intended as open-label treatment for approximately 7 subjects who completed Part B of Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Routes of entry into Part C

> “Subject has completed Part B, meets the criteria for dose reduction for a second time or meets the criteria for the rescue option”
> “Subject agrees to convert from the dose of VTS-270 currently receiving as a subject in the NIH phase 1/2a protocol to the dose chosen for Parts B and C of this study, 900 mg;”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

> “One of the following is required for inclusion into VTS301 Part C:”
> “Has agreed to convert from the monthly dosing regimen used in the NIH phase 1/2a protocol to an every 2 weeks dosing regimen”
> “The investigator has received prior written authorization from the sponsor for the participant to enter VTS301 Part C on an amended dose and/or regimen”
> “Has received prior written authorization from Vtesse to enroll directly into Part C”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.4-2"></a>

#### Conditions for continuing treatment after 21 June 2021

> “After 21 June 2021, subjects may not continue to receive IT adrabetadex, except for those subjects (and legally authorized representatives, as appropriate):”
> “who appear to be benefiting from intrathecal adrabetadex based on the investigator’s assessment, AND”
> “who are aware of the risks associated with adrabetadex, including hearing loss, and understand that no significant differences were seen between patients treated with adrabetadex and sham-treated patients on any efficacy measures in this randomized, controlled trial.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.4-3"></a>

#### VTS-270-302 inclusion criteria

> “Participant completed Part B of Study VTS301 (defined as having completed Visit 27/Week 52 or completed at least through Visit 13/Week 24 and required rescue option) and is continuing in Part C of Study VTS301.”
> “Participant, in the opinion of the Principal Investigator, should continue treatment with VTS-270.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Dosage in Part C

> “The LEMBAZ dosage was 900 mg intrathecally every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down to a minimum of 400 milligrams (mg) or up to a maximum of 900 mg, at the investigator's discretion.”
> “Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.”

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.5-2"></a>

#### Dose re-escalation and reduction in Part C

> “If a subject has had his/her dose reduced and is in Part C on a tolerable dose, the subject may be dose titrated back up (e.g., from 400 mg to 600 mg and from 600 mg to 900 mg) to a tolerable dose as determined by the investigator.”
> “During Part C, the same guidelines apply for dose reduction, with each subject for whom dose reduction is considered being individually reviewed with the medical monitor.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.5-3"></a>

#### Dosing of participants from the NIH phase 1/2a trial

> “Rollover participants from Study 13-CH-0001 received adrabetadex at an amended dose and/or regimen after prior written authorization from the sponsor.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.5-4"></a>

#### Rationale for the intrathecal access port

> “Given that VTS-270 does not penetrate the blood-brain barrier and requires IT administration, the ability to administer VTS-270 via the device will obviate the need for biweekly lumbar punctures (LPs), as well as anesthesia, thereby removing a significant burden for subjects and site personnel.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.5-5"></a>

#### VTS-270-302 dosing

> “Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the participant, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.”

Source: [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment

> “Part C may enroll more than 51 subjects.”

Source: [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)

<a id="topic-3.1.3.7.1-2"></a>

##### Participants analyzed by entry group

| Group | Participants analyzed |
| --- | --- |
| Treatment naive | “18” |
| Previously treated in phase I | “13” |
| Previously treated in Part A/B | “35” |
| Total | “66” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.7.1-3"></a>

##### VTS-270-302 planned sample size

> “The sample size for this study is approximately 7 subjects. The sample size was determined based on the potential number of subjects eligible to transition from Study VTS301.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Open-label population

> “The Open-label population included participants who received at least 1 dose of adrabetadex during Part C.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

> “The Part C open‐label population will consists of all subjects who receive at least one dose of VTS‐270 during Part C.”

Source: [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Participant flow and reasons for not completing

| Milestone or reason | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| Started | “18” | “13” | “35” |
| Completed | “0” | “0” | “0” |
| Not completed | “18” | “13” | “35” |
| Adverse event | “1” | “0” | “1” |
| Death | “0” | “0” | “1” |
| Investigator's decision | “0” | “0” | “1” |
| Lost to follow-up | “1” | “0” | “0” |
| Termination by sponsor or regulatory authorities | “8” | “4” | “13” |
| Transferred to EAP following study termination | “0” | “0” | “1” |
| Transferred to Expanded Access Program | “1” | “0” | “0” |
| Transferred to OLEX program | “3” | “0” | “5” |
| Withdrawal by subject | “4” | “9” | “13” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

##### Sources of Part C participants

> “Participants who completed Part B and participants who completed National Institutes of Health (NIH) phase 1 study (Protocol 13-CH-0001) were eligible to participate in this study.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

##### Recorded reason the study stopped

| Field | Quoted record |
| --- | --- |
| Why stopped | “Terminated by previous Sponsor decision” |

Source: [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)

<a id="topic-3.1.3.8.1-4"></a>

##### VTS-270-302 disposition

> “The study has been terminated early by the Sponsor due to previous Sponsor decision.”

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline demographics by entry group

| Characteristic | Treatment naive (n = 18) | Previously treated in phase I (n = 13) | Previously treated in Part A/B (n = 35) | Total (n = 66) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “13.2(5.07)” | “17.5(6.16)” | “14.1(5.60)” | “14.5(5.70)” |
| Female | “10” | “7” | “15” | “32” |
| Male | “8” | “6” | “20” | “34” |
| White | “16” | “13” | “29” | “58” |
| Hispanic or Latino | “3” | “1” | “2” | “6” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

##### VTS-270-302 baseline reporting

> “No data is reported here to maintain participant confidentiality.”

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Efficacy endpoints not reported after January 2021

> “Part C: After 20 January 2021, efficacy endpoints for Part C will not be reported.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.8.3-2"></a>

##### VTS-270-302: efficacy assessments discontinued

> “Efficacy assessments will not be performed and existing efficacy data will not be analyzed.”

Source: [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Primary outcome: participants with TEAEs and SAEs

| Outcome | Treatment naive (n = 18) | Previously treated in phase I (n = 13) | Previously treated in Part A/B (n = 35) |
| --- | --- | --- | --- |
| Any TEAEs | “18” | “13” | “34” |
| SAEs | “9” | “7” | “20” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

##### Deaths and serious adverse events

| Event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| All-cause mortality | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Any serious adverse event | “9/18 (50.00%)” | “7/13 (53.85%)” | “20/35 (57.14%)” |
| Dysphagia | “1/18 (5.56%)” | “0/13 (0.00%)” | “4/35 (11.43%)” |
| Pneumonia aspiration | “1/18 (5.56%)” | “0/13 (0.00%)” | “3/35 (8.57%)” |
| Pneumonia | “1/18 (5.56%)” | “2/13 (15.38%)” | “1/35 (2.86%)” |
| Back pain | “3/18 (16.67%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Deafness neurosensory | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis bacterial | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis staphylococcal | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Spinal subdural haematoma | “1/18 (5.56%)” | “0/13 (0.00%)” | “0/35 (0.00%)” |
| Spinal subarachnoid haemorrhage | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Device dislocation | “0/18 (0.00%)” | “0/13 (0.00%)” | “2/35 (5.71%)” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-3"></a>

##### Common non-serious adverse events

| Adverse event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
| --- | --- | --- | --- |
| Any other (non-serious) adverse event | “18/18 (100.00%)” | “13/13 (100.00%)” | “34/35 (97.14%)” |
| Vomiting | “12/18 (66.67%)” | “9/13 (69.23%)” | “16/35 (45.71%)” |
| Hypoacusis | “9/18 (50.00%)” | “4/13 (30.77%)” | “9/35 (25.71%)” |
| Headache | “9/18 (50.00%)” | “9/13 (69.23%)” | “12/35 (34.29%)” |
| Ataxia | “9/18 (50.00%)” | “2/13 (15.38%)” | “8/35 (22.86%)” |
| Fatigue | “8/18 (44.44%)” | “5/13 (38.46%)” | “13/35 (37.14%)” |
| Pyrexia | “6/18 (33.33%)” | “9/13 (69.23%)” | “17/35 (48.57%)” |
| Fall | “5/18 (27.78%)” | “7/13 (53.85%)” | “16/35 (45.71%)” |
| Gait disturbance | “2/18 (11.11%)” | “6/13 (46.15%)” | “10/35 (28.57%)” |

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

##### Termination of device implantation after catheter tip migration

> “Device implantations were terminated in August 2018 following reports of the catheter tip migrating from the IT space in some subjects.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

<a id="topic-3.1.3.8.5-5"></a>

##### VTS-270-302 safety

| Outcome | Adrabetadex (n = 2) |
| --- | --- |
| All TEAEs, participants | “2” |
| SAEs, participants | “0” |
| All-cause mortality | “0/2 (0.00%)” |

Source: [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: design limitations of Part C

- Control and blinding: Part C was an open-label extension in which all participants received study drug, and the sponsor gave it a separate registration because of its different study design.
- Mixed population and dosing: Part C enrolled 66 participants, comprising 35 LEMBAZ-treated participants from Parts A and B, 18 treatment-naïve participants, and 13 LEMBAZ-treated patients from Trial 2. The dose could be adjusted between 400 mg and 900 mg at the investigator's discretion, and rollover participants from Study 13-CH-0001 received an amended dose and/or regimen.
- Missing efficacy collection: the planned efficacy endpoints included the NPC-SS composite and the EQ-5D-3L. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective of Part C was changed to longer-term safety and tolerability only, and efficacy endpoints after 20 January 2021 were not reported.
- Early termination: the sponsor discontinued the development program and terminated Part C. No participant completed the study (0 of 18 treatment-naive, 0 of 13 previously treated in phase I, and 0 of 35 previously treated in Part A/B); termination by sponsor or regulatory authorities accounted for 8, 4, and 13 participants and withdrawal by subject for 4, 9, and 13.
- Selective continuation: after 21 June 2021, only subjects who appeared to be benefiting in the investigator's assessment, and who understood that no significant differences were seen between adrabetadex and sham on any efficacy measure in the randomized trial, could continue treatment.
- Substudies: the planned European plasma and CSF pharmacokinetic substudy of administration through the device was not conducted because no subjects consented.
- VTS-270-302 continuation study: planned for approximately 7 subjects, it enrolled 2, was terminated early by the sponsor, did not perform efficacy assessments or analyze existing efficacy data, and reported no baseline data to maintain participant confidentiality.

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642); [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results); [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf); [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf); [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf); [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655); [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-3.1.3.9-2"></a>

#### Termination of Part C by the sponsor

> “The development program for adrabetadex was discontinued and Part C of the study was terminated by the Sponsor.”

Source: [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)

> “The Sponsor has discontinued the VTS-270 development program following determination of a negative benefit/risk balance.”

Source: [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
